FABP1 and liver dysplastic nodule: A multicenter randomized, double-blind, placebo-controlled trial on the efficacy of Tangshen Formula in DN yielded promising results: after a mere 6 months, the improvements in proteinuria and estimated glomerular filtration rate (eGFR) were significant [124], as was the decrease in liver-type fatty acid binding protein [125], a biomarker correlated with the severity and prognosis of DN [126].